An up-to-date anti-cancer treatment strategy focusing on HIF-1α suppression: Its application for refractory ovarian cancer

Acta Histochemica et Cytochemica

Volumn 40, Issue 5, 2007, Pages 139-142

  Fujita, Mariko ^a   Yasuda, Masanori ^b   Kitatani, Kanae ^a   Miyazawa, Masaki ^a   Hirabayashi, Kenichi ^a   Takekoshi, Susumu ^a   Iida, Tetsuji ^a   Hirasawa, Takeshi ^a   Murakami, Masaru ^a   Mikami, Mikio ^a   Ishiwata, Isamu ^c   Shimizu, Michio ^b   Osamura, R Yoshiyuki ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^c Ishiwata Obstetrics and Gynecology Hospital

Author keywords

Clear cell adenocarcinoma; GLUT 1; HIF 1 ; Rapamycin; VEGF

Indexed keywords

GLUCOSE TRANSPORTER 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; RAPAMYCIN; VASCULOTROPIN;

ARTICLE; CANCER CELL; CANCER THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 37549042410     PISSN: 00445991     EISSN: 13475800     Source Type: Journal    
DOI: 10.1267/ahc.07024     Document Type: Article

References (24)

1. Atkins, M. B., Hidalgo, M., Stadler, W. M., Logan, T. F., Dutcher, J. P., Hudes, G. R., Park, Y., Liou, S. H., Marshall, B., Boni, J. P., Dukart, G. and Sherman, M. L. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J. Clin. Oncol. 22; 909-918.
2. Birner, P., Schindl, M., Obermair, A., Plank, C., Breitenecker, G. and Oberhuber, G. (2000) Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in earlystage invasive cervical cancer. Cancer Res. 60; 4693-4696.
3. Birner, P., Schindl, M., Obermair, A., Breitenecker, G. and Oberhuber, G. (2001) Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7; 1661-1668.
4. Bos, R., Zhong, H., Hanrahan, C. F., Mommers, E. C., Semenza, G. L., Pinedo, H. M., Abeloff, M. D., Simons, J. W., van Diest, P. J. and van der Wall, E. (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst. 93; 309-314.
5. Boulay, A., Rudloff, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S. and Lane, H. A. (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin. Cancer Res. 11; 5319-5328.
6. Cantuaria, G., Magalhaes, A., Penalver, M., Angioli, R., Braunschweiger, P., Gomez-Marin, O., Kanhoush, R., Gomez-Fernandez, C. and Nadji, M. (2000) Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol. Oncol. 79; 33-37.
7. Cantuaria, G., Fagotti, A., Ferrandina, G., Magalhaes, A., Nadji, M., Angioli, R., Penalver, M., Mancuso, S. and Scambia, G. (2001) GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer 92; 1144-1150.
8. Ikeda, E. (2005) Cellular response to tissue hypoxia and its involvement in disease progression. Pathol. Int. 55; 603-610.
9. Jiang, H. and Feng, Y. (2006) Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer. Int. J. Gynecol. Cancer 1; 405-412.
10. Kalir, T., Wang, B. Y., Goldfischer, M., Haber, R. S., Reder, I., Demopoulos, R., Cohen, C. J. and Burstein, D. E. (2002) Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. Cancer 94; 1078-1082.
11. Kimbro, K. S. and Simons, J. W. (2006) Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr. Relat. Cancer 13; 739-749.
12. Lee, S., Garner, E. I., Welch, W. R., Berkowitz, R. S. and Mok, S. C. (2007) Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol. Oncol. 106; 311-317.
13. Mabuchi, S., Altomare, D. A., Connolly, D. C., Klein-Szanto, A., Litwin, S., Hoelzle, M. K., Hensley, H. H., Hamilton, T. C. and Testa, J. R. (2007) RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 67; 2408-2413.
14. Maxwell, P. H., Wiesener, M. S., Chang, G. W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R. and Ratcliffe, P. J. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399; 271-275.
15. Noguchi, Y., Saito, A., Miyagi, Y., Yamanaka, S., Marat, D., Doi, C., Yoshikawa, T., Tsuburaya, A., Ito, T. and Satoh, S. (2000) Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett. 154; 175-182.
16. Osada, R., Horiuchi, A., Kikuchi, N., Yoshida, J., Hayashi, A., Ota, M., Katsuyama, Y., Mellilo, G. and Konishi, I. (2007) Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum. Pathol. 38; 1310-1320.
17. Semenza, G. L. (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8; 62-67.
18. Semenza, G. L. (2003) Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3; 721-732.
19. Semenza, G. L. and Wang, G. L. (1992) A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell Biol. 12; 5447-5454.
20. Treek, O., Wackwitz, B., Haus, U. and Ortmann, O. (2006) Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol. Oncol. 102; 292-299.
21. Wong, C., Wellman, T. L. and Lounsbury, K. M. (2003) VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol. Oncol. 91; 513-517.
22. Yasuda, M., Ogane, N., Hayashi, H., Miyagi, Y., Iida, T., Mori, Y., Tsukinoki, K., Minematsu, T. and Osamura, Y. (2005) Glucose transporter-1 expression in the thyroid gland: clinicopathological significance for papillary carcinoma. Oncol. Rep. 14; 1499-1504.
23. Yasuda, M., Miyazawa, M., Fujita, M., Kajiwara, H., Iida, T., Hirasawa, T., Muramatsu, T., Murakami, M., Mikami, M., Saitoh, K., Shimizu, M., Takekoshi, S. and Osamura, R. Y. (2007) Expression of hypoxia inducible factor-1α (HIF-1α) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: Difference in hypoxic status depending in histological character. Oncol. Rep. (in press).
24. Zagzag, D., Zhong, H., Scalzitti, J. M., Laughner, E., Simons, J. W. and Semenza, G. L. (2000) Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer 88; 2606-2618.